IOM Report Takes Aim at Conflict

June 2009
Pharmaceutical Representative;Jun2009, Vol. 39 Issue 6, p9
The article focuses on the report issued by the Institute of Medicine (IOM) in the U.S. concerning conflicts of interest between physicians and pharmaceutical sales representatives. IOM calls for limitations on the interactions between the two and physicians use of free drug samples. Robert Steinbrook of "The New England Journal of Medicine," stresses the comprehensiveness of the proposal and its possible significant effects to physicians and medical institutions.


Related Articles

  • US Institute of Medicine report calls for an end to firms' drug and device promotion to doctors. Roehr, Bob // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;5/9/2009, Vol. 338 Issue 7703, p1100 

    The article focuses on a 2009 report which was released by the U.S. Institute of Medicine. In the report the institute suggests that product promotion among doctors by drug companies and medical device manufacturers should be virtually eliminated, and that any remaining research and educational...

  • Physician assistants for sale: Will prescribe for food. ANDERSON, JIM // JAAPA: Journal of the American Academy of Physician Assistants (;Aug2011, Vol. 24 Issue 8, p57 

    The article focuses on the influence of pharmaceutical representatives in the prescribing decisions of health care providers. It cites that the Institute of Medicine (IoM) emphasizes the need for both providers and representatives to address conflict of interest in drug prescribing. The author...

  • Controlling Conflict of Interest � Proposals from the Institute of Medicine. Steinbrook, Robert // New England Journal of Medicine;5/21/2009, Vol. 360 Issue 21, p2160 

    The article reflects upon a report by the U.S. Institute of Medicine (IOM) on conflict of interest between physicians and industry. The author discusses the meaning of a conflict of interest and the intent of the IOM to balance the benefits industry affiliations provide with the risks of...

  • Harmonizing Reporting of Financial Conflicts. Kuehn, Bridget M. // JAMA: Journal of the American Medical Association;1/2/2013, Vol. 309 Issue 1, p19 

    The article focuses on the report released by the participants of the U.S. organization Institute of Medicine (IOM) efforts which suggest a Harmonized System that is used for reporting conflicts of interest should ease the burden of reporting and promote the transparency.

  • Influencing Physicians. Retsinas, Joan // Progressive Populist;6/15/2009, Vol. 15 Issue 11, p15 

    The article discusses the influence of pharmaceutical companies to physicians which could physicians medical decision-making for their patients. It notes several ways in which influence are exerted, including free pens and notepads with a logo of the company, free lectures and part-time jobs...

  • Conflict of Interest Policies for Organizations Producing a Large Number of Clinical Practice Guidelines. Norris, Susan L.; Holmer, Haley K.; Burda, Brittany U.; Ogden, Lauren A.; Fu, Rongwei // PLoS ONE;May2012, Vol. 7 Issue 5, p1 

    Background: Conflict of interest (COI) of clinical practice guideline (CPG) sponsors and authors is an important potential source of bias in CPG development. The objectives of this study were to describe the COI policies for organizations currently producing a significant number of CPGs, and to...

  • 'Conflict of interest' outdated phrase for physician-industry relationship? Brannon, Matthew; Raible, Eric // Endocrine Today;May2010, Vol. 8 Issue 5, p1 

    The article explores the conflict of interest associated with the collaborative relationship between physicians and the pharmaceutical industry.

  • CAPITAL CAPSULES. Conlan, Michael F. // Drug Topics;3/6/2000, Vol. 144 Issue 5, p30 

    Presents updates on the pharmaceutical industry in the United States as of March 6, 2000. Information on US President Bill Clinton's endorsement of the key recommendations of the Institute of Medicine report on medical errors; Obstacle faced by the House Democrats in getting floor votes on Rxs...

  • IOM : Time to Share Data.  // Chain Drug Review;2/16/2015, Vol. 37 Issue 4, p56 

    The article reports that a study by the U.S. Institute of Medicine (IOM) has recommended that drug companies, device manufacturers and government agencies share data from research studies, which they jointly fund.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics